What to watch with FADS1 and allergy?

FADS1 encodes a key enzyme in the conversion of polyunsaturated fatty acids (omega-3 and omega-6) into their bioactive forms. Certain variants (e.g., rs174546) have been linked in GWAS to a modestly increased risk of atopic diseases such as eczema, asthma, and hay fever. The effect size is small (odds ratio ~1.1–1.3) and strongly modulated by diet: higher omega-3 intake (fish, flaxseed) may partially offset the genetic risk. Evidence comes mainly from observational studies and GWAS; randomized controlled trials stratifying by FADS1 genotype are limited. A DNA test alone cannot diagnose allergies – environmental factors, microbiome, and immune status play larger roles. MyBody-X can detect FADS1 variants, but results should not be the sole basis for supplementation or dietary changes. Caution is warranted: personalized allergy prevention based on a single gene lacks robust clinical validation.